Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

Merck Sharp & Dohme (MSD)

Status and phase: Enrolling; Phase 3

Conditions: Metastatic Esophageal Squamous Cell Carcinoma

Treatments: Drug: Oxaliplatin; Drug: Levoleucovorin; Drug: Paclitaxel; Drug: Leucovorin; Drug: Lenvatinib; Biological: Pembrolizumab; Drug: Cisplatin; Drug: 5-FU

Study type: Interventional

Funder types: Industry

Identifiers

NCT04949256

LEAP-014 (Other Identifier)

2022-501342-29 (Registry Identifier)

U1111-1280-1020 (Other Identifier)

MK-7902-014 (Other Identifier)

7902-014

2020-001911-26 (EudraCT Number)

E7080-G000-320 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal carcinoma.

The primary hypotheses are that pembrolizumab plus lenvatinib plus chemotherapy is superior to pembrolizumab plus chemotherapy with respect to overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

Full description

There will be 2 parts to the study: the cisplatin and 5-fluorouracil (5-FU) (FP) and paclitaxel and cisplatin (TP) Safety Run-in (Part 1) and the Main Study (Part 2). In Part 1 (FP and TP Safety Run-in), participants will be treated with pembrolizumab plus lenvatinib plus FP or TP. Dose-limiting toxicities, safety, and tolerability will be assessed.

In Part 2 (Main Study), participants (not including those participating in Part 1) will be treated with pembrolizumab plus lenvatinib plus chemotherapy or pembrolizumab plus chemotherapy. Efficacy, safety, and tolerability will be assessed.

Enrollment: 862 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Has a histologically or cytologically confirmed diagnosis of metastatic squamous cell carcinoma of the esophagus
• Male participants are abstinent from heterosexual intercourse or agree to use contraception during the intervention period and for at least 7 days after the last dose of lenvatinib or 90 days after the last dose of chemotherapy, whichever comes last; 7 days after lenvatinib is stopped, if the participant is on pembrolizumab only and is greater than 90 days post chemotherapy, no male contraception is needed
• Female participant is not pregnant or breastfeeding and is not a woman of childbearing potential (WOCBP) or is a WOCBP using a contraceptive method that is highly effective or is abstinent from heterosexual intercourse as their preferred and usual lifestyle during the intervention period and for at least 120 days after the last dose of pembrolizumab, 30 days after the last dose of lenvatinib, or 180 days after the last dose of chemotherapy, whichever occurs last, and agrees not to donate eggs during this period
• Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP≤150/90 millimeters of mercury (mm Hg) with no change in antihypertensive medications within 1 week prior to randomization
• Has adequate organ function

Exclusion criteria

• Has had previous therapy for locally advanced unresectable or metastatic esophageal cancer
• Has locally advanced esophageal carcinoma
• Has metastatic adenocarcinoma of the esophagus
• Has direct invasion into adjacent organs such as the aorta or trachea
• Has radiographic evidence of encasement of a major blood vessel, or of intratumoral cavitation
• Has perforation risks or significant gastrointestinal (GI) bleeding
• Has had clinically significant hemoptysis within 3 weeks prior to the first dose of study drug or tumor bleeding within 2 weeks prior to the first dose of study intervention
• Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage or medical intervention
• Has GI obstruction, poor oral intake, difficulty in taking oral medication, or existing esophageal stent
• Has had major surgery, open biopsy, or significant traumatic injury within 3 weeks prior to first dose of study interventions
• Has received prior radiotherapy within 2 weeks of start of study intervention or have had a history of radiation pneumonitis
• Has received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention; administration of killed vaccines is allowed
• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any form of immunosuppressive therapy within 7 days prior to the first dose of study intervention, or has a history of organ transplant, including allogeneic stem cell transplant
• Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
• Has an active autoimmune disease that has required systemic treatment in past 2 years; replacement therapy is not considered a form of systemic treatment and is allowed
• Has a history of non-infectious pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease
• Has poorly controlled diarrhea
• Has clinically significant cardiovascular disease within 12 months from first dose of study intervention
• Has peripheral neuropathy ≥Grade 2
• Has a known history of human immunodeficiency virus (HIV) infection
• Has a known history of Hepatitis B or know active Hepatitis C virus infection
• Has a weight loss of >20% within the last 3 months

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

862 participants in 3 patient groups

Part 1: Pembrolizumab + Lenvatinib + Chemotherapy

Experimental group

Description:

In the induction phase, participants receive pembrolizumab 400mg intravenously (IV) every 6 weeks (Q6W) for 2 cycles (each cycle length = 6 weeks) plus Lenvatinib 8 mg orally (PO) once daily (QD) plus chemotherapy with FP (cisplatin 80 mg/m\^2 and 5-FU 400 mg/m\^2 followed by 2400 mg/m\^2) or TP (paclitaxel 175 mg/m\^2 and cisplatin 75 mg/m\^2) IV every 3 weeks for 4 administrations at the investigator's discretion (approximately 12 weeks). In the consolidation phase, participants receive pembrolizumab 400 mg IV Q6W for 16 cycles (each cycle length = 6 weeks) and Lenvatinib 20 mg PO until progressive disease or discontinuation (approximately 96 weeks).

Treatment:

Drug: 5-FU

Drug: Cisplatin

Biological: Pembrolizumab

Drug: Lenvatinib

Drug: Paclitaxel

Part 2: Pembrolizumab + Lenvatinib + Chemotherapy

Experimental group

Description:

In the induction phase, participants receive pembrolizumab 400mg intravenously (IV) every 6 weeks (Q6W) for 2 cycles (each cycle length = 6 weeks) plus Lenvatinib 8 mg orally (PO) once daily (QD) plus chemotherapy with FP (cisplatin 80 mg/m\^2 and 5-FU 4000 mg/m\^2) or TP (paclitaxel 175 mg/m\^2 and cisplatin 75 mg/m\^2) IV every 3 weeks for 4 administrations or mFOLFOX6 (oxaliplatin 85 mg/m\^2, 5-FU 400 mg/m\^2 followed by 2400 mg/m\^2, and leucovorin 400 mg/m\^2 \[or levoleucovorin 200 mg/m\^2\] once every 2 weeks \[Q2W\] for 6 administrations at the investigator's discretion (approximately 12 weeks). In the consolidation phase, participants receive pembrolizumab 400 mg IV Q6W for 16 cycles (each cycle length = 6 weeks) and Lenvatinib 20 mg PO until progressive disease or discontinuation (approximately 96 weeks).

Treatment:

Drug: 5-FU

Drug: Cisplatin

Biological: Pembrolizumab

Drug: Lenvatinib

Drug: Leucovorin

Drug: Paclitaxel

Drug: Levoleucovorin

Drug: Oxaliplatin

Part 2: Pembrolizumab + Chemotherapy

Active Comparator group

Description:

Participants receive pembrolizumab 400 mg IV every 6 weeks for 18 cycles (each cycle length = 6 weeks, approximately 2 years) plus chemotherapy with FP (cisplatin 80 mg/m\^2 IV Q3W for up to 6 administrations \[up to \~18 weeks\] and 5-FU 4000 mg/m\^2 IV Q3W for up to 35 administrations \[up to \~2 years\]) or TP (paclitaxel 175 mg/m\^2 and cisplatin 75 mg/m\^2 Q3W for up 6 administrations \[up to \~18 weeks\]) or in combination with mFOLFOX6 (oxaliplatin 85 mg/m\^2, 5-FU 400 mg/m\^2 followed by 2400 mg/m\^2 and leucovorin 400 mg/m\^2 \[or levoleucovorin 200 mg/m\^2\] IV Q2W for up to 52 administrations \[approximately 2 years\]).

Treatment:

Drug: 5-FU

Biological: Pembrolizumab

Drug: Leucovorin

Drug: Paclitaxel

Drug: Levoleucovorin

Drug: Oxaliplatin